Biomarin Pharmaceutical Inc (B1MR34)


Symbol	Exchange	Currency
B1MR34	B3	BRL	Delayed
BMRN	NASDAQ	USD	Real-time
1BMRN	Milan	EUR	Real-time
BMRN	TradeGate	EUR	Delayed
BMRN	Vienna	EUR	Real-time

Currency in BRL

Disclaimer

252.20

0.00(0.00%)

Delayed Data04/09

Fair Value

Unlock Value

Day's Range

250.38

256.01

52 wk Range

195.19

258.34

B1MR34 Cash Flow Statement
Featured here, the Cash Flow Statement for Biomarin Pharmaceutical Inc, showing the changes in the company's cash and cash equivalents, broken down to operating, investing and financing activities over each of the last 10 periods (either quarterly or annually).

Advanced Cash Flow Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Cash from Operations

aa.aa

48.26

85.37

304.54

175.9

159.26

	Cash from Operations Growth
	Net Income
	Depreciation & Amortisation, Total
	Amortisation of Deferred Charges, Total
	Other Non-Cash Items, Total
	Change in Net Operating Assets

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+138.83%	+76.88%	+256.75%	-42.24%	-9.46%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-23.85	854.03	-64.08	141.56	167.65
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	105.3	105.17	108.04	101.97	104.39
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	67.9	-648.9	194.54	28.76	223.77
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-101.09	-224.94	66.03	-96.38	-336.54

Cash from Investing

aa.aa

-31.03

-53.62

-366.31

-20.03

-111.24

	Cash from Investing Growth
	Capital Expenditure
	Sale of Property, Plant, and Equipment
	Cash Acquisitions
	Divestitures
	Other Investing Activities

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-111.74%	-72.83%	-583.15%	+94.53%	-455.41%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-145.03	-114.31	-95.58	-120.96	-96.69
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	114	60.69	-270.74	100.93	-14.55

Cash from Financing

aa.aa

-74.67

181.12

-0.05

-18.65

-18.73

	Cash from Financing Growth
	Total Debt Issued
	Short Term Debt Issued, Total
	Long-Term Debt Issued, Total
	Total Debt Repaid
	Short Term Debt Repaid, Total
	Long-Term Debt Repaid, Total
	Issuance of Common Stock
	Repurchase of Common Stock
	Issuance of Preferred Stock
	Repurchase of Preferred Stock
	Common & Preferred Stock Dividends Paid
	Special Dividend Paid
	Other Financing Activities
	Foreign Exchange Rate Adjustments
	Miscellaneous Cash Flow Adjustments

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+80.75%	+342.54%	-100.03%	-38,754.17%	-0.41%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	585.75	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	585.75	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-5.09	-381.91	-3.04	-2.61	-2.29
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-5.09	-381.91	-3.04	-2.61	-2.29
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	31.61	71.91	49.19	69.33	69.35
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-42.68	-94.64	-45.81	-54.28	-76.32
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-58.52	-	-0.4	-31.1	-9.48
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	0.9	-1.15	-0.06	0.03	1.31
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Net Change in Cash

aa.aa

-56.54

211.71

-61.88

137.26

30.6

	Beginning Cash Balance
	Ending Cash Balance
	Levered Free Cash Flow
	Levered Free Cash Flow Growth
	Free Cash Flow Yield

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	493.98	437.45	649.16	587.28	724.53
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	437.45	649.16	587.28	724.53	755.13
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-133.19	-18.77	201.61	146.25	-25.9
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-97.7%	+85.91%	+1,174.14%	-27.46%	-117.71%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-0.6	0.09	1.15	0.77	0.29

* In Millions of USD (except for per share items)

South Africa Top 40

73,924.07

+49.88

+0.07%

S. Africa 40 Futures

73,759.00

-136

-0.18%

US 30

40,766.10

+420.7

+1.04%

US 500

5,453.80

+45.4

+0.84%

US Tech 100

18,555.60

+131.9

+0.72%

DAX Futures

18,477.50

+170.5

+0.93%

Dollar Index

101.522

+0.379

+0.37%

Market Movers

Name	Last	Chg. %	Vol.
FirstRand Ltd	8,536	+0.66%	7.77M
MTN	9,155	-0.40%	3.94M
ABSA	17,194	+0.33%	2.13M
Standard Bank	23,408	+0.20%	1.93M
British American Tobacco	69,436	+1.45%	757.51K
Capitec	295,425	+2.70%	309.18K
Naspers	354,928	+0.37%	240.72K

Name	Last	Chg. %	Vol.
Acsion	1,049	+39.68%	216.00
Metrofile	210	+15.38%	110.81K
Premier	8,000.00	+12.04%	64.44K
RH Bophelo	207	+7.25%	9.04K
Oando Plc	45	+7.14%	25.00K
Merafe	142	+6.77%	11.66M
Orion Gold NL	20	+5.26%	4.34M

Name	Last	Chg. %	Vol.
Globe Trade Centre	3,000	-25.00%	5.00K
Ayo Tech	40	-20.00%	45.40K
Brikor	14.00	-17.65%	34.35K
Sebata Holdings	100	-16.67%	324.00
E Media Holdings Ltd	318	-14.05%	1.00K
Goldrush Holdings Prf	702	-9.42%	7.33K
Kore Potash	54.00	-6.90%	1.93M

Trending Stocks

Name	Last	Chg. %	Vol.
Sibanye Stillwater	1,522	-4.04%	12.14M
Impala Platinum	7,137	-4.50%	4.05M
MTN	9,155	-0.40%	3.94M
Capitec	295,425	+2.70%	309.18K
Sasol	12,400	-2.24%	2.00M

Popular Searches

Please try another search

Biomarin Pharmaceutical Inc (B1MR34)

B1MR34 Cash Flow Statement
Featured here, the Cash Flow Statement for Biomarin Pharmaceutical Inc, showing the changes in the company's cash and cash equivalents, broken down to operating, investing and financing activities over each of the last 10 periods (either quarterly or annually).

Trending Stocks

Please try another search

Biomarin Pharmaceutical Inc (B1MR34)

B1MR34 Cash Flow StatementFeatured here, the Cash Flow Statement for Biomarin Pharmaceutical Inc, showing the changes in the company's cash and cash equivalents, broken down to operating, investing and financing activities over each of the last 10 periods (either quarterly or annually).

Trending Stocks

B1MR34 Cash Flow Statement
Featured here, the Cash Flow Statement for Biomarin Pharmaceutical Inc, showing the changes in the company's cash and cash equivalents, broken down to operating, investing and financing activities over each of the last 10 periods (either quarterly or annually).